Soluble epidermal growth factor receptor (EGFR) and HER-2 monitoring in a Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell lung cancer (NSCLC)

M P Gatineau,O Rixe,E Lemarie,S Oudard,S Kalla,F Chomy,R Mouawad,P Nouyrigat,E Dansin,D Khayat

doi:10.1200/jco.2004.22.90140.7090

Soluble epidermal growth factor receptor (EGFR) and HER-2 monitoring in a Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell lung cancer (NSCLC)

M P Gatineau, O Rixe + Show 8 more

https://doi.org/10.1200/jco.2004.22.90140.7090

Copy DOI

Journal: Journal of Clinical Oncology

Publication Date: Jul 15, 2004

Affiliation: Institut Bergonié, Centre Oscar Lambret, AstraZeneca (France), Centre Hospitalier Universitaire de Tours

#Soluble Epidermal Growth Factor Receptor #Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

7090 Background: We previously reported the preliminary activity and tolerability of the combination of the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) and docetaxel in patients wit...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.